Bispecific antibodies (bsAbs) are one of biotech’s most exciting therapeutic classes, promising the ability to bind two different targets simultaneously — unlocking new treatment possibilities in oncology, immunology, and beyond. But despite the buzz, the sobering truth from industry insiders is this: most bispecific programs collapse long before they ever hit GMP manufacturing at a […]
In the fast-evolving world of bacteriophage therapy, host range testing isn’t just another box to tick—it’s the make-or-break step that defines whether your phage will perform where it matters most: in the real world. This crucial process reveals exactly which bacterial strains a phage can attack, how wide or narrow its kill zone is, and […]
In a bold move that underscores the strategic importance of contract development and manufacturing organizations (CDMOs) in the biotech industry, SamsungBiologics, a preeminent player in biologics manufacturing, inked a mammoth $668 million contract with a Europe-based pharmaceutical firm in November 2024. This alliance not only signals a significant leap in SamsungBiologics’ stature but also showcases […]
Avid Bioservices and Eliem Therapeutics, both NASDAQ-listed medical companies, are compared based on institutional ownership, earnings, analyst recommendations, valuation, profitability, dividends, and risk. Avid Bioservices has a higher volatility but stronger consensus rating and possible upside compared to Eliem Therapeutics. With 97.2% institutional ownership, Avid Bioservices is favored by hedge funds and large money managers. […]
Contract Development and Manufacturing Organizations (CDMOs) specializing in fermentation and biomolecule production face complex contamination risks that can jeopardize batch integrity, regulatory compliance, and product efficacy. While spore-forming bacteria (sporocidal challenges) are a well-known concern, contamination threats extend far beyond spores. These risks, if left unmanaged, can result in costly recalls, compromised therapeutic potency, and […]
